thalidomide has been researched along with Cachexia in 44 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Cachexia: General ill health, malnutrition, and weight loss, usually associated with chronic disease.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine the effects of thalidomide and placebo on anorexia-cachexia and its related symptoms, body composition, resting metabolic rate, and serum cytokines and their receptors in patients with advanced cancer." | 9.16 | The role of thalidomide and placebo for the treatment of cancer-related anorexia-cachexia symptoms: results of a double-blind placebo-controlled randomized study. ( Allo, J; Bruera, E; Cohen, EN; Del Fabbro, E; Palmer, JL; Reuben, JM; Tin, S; Willey, JS; Yennurajalingam, S, 2012) |
| "Thalidomide was well tolerated and effective at attenuating loss of weight and lean body mass in patients with cachexia due to advanced pancreatic cancer." | 9.11 | Thalidomide in the treatment of cancer cachexia: a randomised placebo controlled trial. ( Duncan, HD; Ellis, RD; Goggin, PM; Gordon, JN; Johns, T; Trebble, TM, 2005) |
| "Celgene Corporation initiated a phase II safety and efficacy trial for Synovir (thalidomide) in the treatment of chronic intractable diarrhea in HIV-positive patients." | 9.08 | Thalidomide used to treat chronic diarrhea in HIV-positive patients. ( , 1996) |
| "This review aimed to (1) evaluate the effectiveness of thalidomide, and (2) identify and assess adverse effects from thalidomide for cancer cachexia." | 8.88 | Thalidomide for managing cancer cachexia. ( Cantwell, M; Cardwell, CR; Donnelly, M; Mills, M; Murray, LJ; Reid, J, 2012) |
| "To discuss and assess the clinical value of treating lung cancer cachexia with thalidomide combined with cinobufagin." | 7.88 | Clinical study on thalidomide combined with cinobufagin to treat lung cancer cachexia. ( Bao, Y; Bu, K; Chen, X; Lu, Y; Qin, S; Xie, M, 2018) |
| "Using our rat cholangiocarcinoma model, we demonstrated that thalidomide inhibited tumor growth and was associated with a decrease in expression of reduced eIF4E and VEGF expression; in addition, thalidomide preserved fast-twitch skeletal muscle fibers and was associated with decreased expression of TNFalpha and TGFbeta1." | 7.74 | Thalidomide attenuates tumor growth and preserves fast-twitch skeletal muscle fibers in cholangiocarcinoma rats. ( Liao, LM; Liu, KH; Ro, LS; Wu, YL; Yeh, TS, 2008) |
| "The management of cancer-related anorexia/cachexia syndrome (CACS) is a great challenge in clinical practice." | 6.77 | Clinical studies on the treatment of cancer cachexia with megestrol acetate plus thalidomide. ( Cao, YZ; Li, X; Peng, LM; Shi, YM; Wen, HS; Yang, F; Zhang, CC, 2012) |
| "Thalidomide treatment appeared to reverse the loss of weight and lean body mass over the 2-week trial period." | 6.71 | Oesophageal cancer and cachexia: the effect of short-term treatment with thalidomide on weight loss and lean body mass. ( Austin, A; Cole, AT; Freeman, JG; Holt, M; Khan, ZH; MacDonald, I; Pye, D; Simpson, EJ, 2003) |
| "To determine the effects of thalidomide and placebo on anorexia-cachexia and its related symptoms, body composition, resting metabolic rate, and serum cytokines and their receptors in patients with advanced cancer." | 5.16 | The role of thalidomide and placebo for the treatment of cancer-related anorexia-cachexia symptoms: results of a double-blind placebo-controlled randomized study. ( Allo, J; Bruera, E; Cohen, EN; Del Fabbro, E; Palmer, JL; Reuben, JM; Tin, S; Willey, JS; Yennurajalingam, S, 2012) |
| "Three hundred thirty-two assessable patients with cancer-related anorexia/cachexia syndrome were randomly assigned to one of five treatment arms: arm 1, medroxyprogesterone (500 mg/day) or megestrol acetate (320 mg/day); arm 2, oral supplementation with eicosapentaenoic acid; arm 3, L-carnitine (4 g/day); arm 4, thalidomide (200 mg/day); and arm 5, a combination of the above." | 5.14 | Randomized phase III clinical trial of five different arms of treatment in 332 patients with cancer cachexia. ( Contu, P; Dessì, M; Macciò, A; Madeddu, C; Mantovani, G; Massa, E; Panzone, F; Serpe, R, 2010) |
| "Three hundred and thirty-two assessable patients with cancer-related anorexia/cachexia syndrome (CACS) were randomly assigned to one of five arms of treatment: 1--medroxyprogesterone 500 mg/d or megestrol acetate 320 mg/d; 2--oral supplementation with eicosapentaenoic acid (EPA); 3--L-carnitine 4 g/d; 4--thalidomide 200 mg/d; 5--a combination of the above." | 5.14 | Randomised phase III clinical trial of 5 different arms of treatment on 332 patients with cancer cachexia. ( Mantovani, G, 2010) |
| "Thalidomide was well tolerated and effective at attenuating loss of weight and lean body mass in patients with cachexia due to advanced pancreatic cancer." | 5.11 | Thalidomide in the treatment of cancer cachexia: a randomised placebo controlled trial. ( Duncan, HD; Ellis, RD; Goggin, PM; Gordon, JN; Johns, T; Trebble, TM, 2005) |
| "Celgene Corporation initiated a phase II safety and efficacy trial for Synovir (thalidomide) in the treatment of chronic intractable diarrhea in HIV-positive patients." | 5.08 | Thalidomide used to treat chronic diarrhea in HIV-positive patients. ( , 1996) |
| "This review aimed to (1) evaluate the effectiveness of thalidomide, and (2) identify and assess adverse effects from thalidomide for cancer cachexia." | 4.88 | Thalidomide for managing cancer cachexia. ( Cantwell, M; Cardwell, CR; Donnelly, M; Mills, M; Murray, LJ; Reid, J, 2012) |
| "To discuss and assess the clinical value of treating lung cancer cachexia with thalidomide combined with cinobufagin." | 3.88 | Clinical study on thalidomide combined with cinobufagin to treat lung cancer cachexia. ( Bao, Y; Bu, K; Chen, X; Lu, Y; Qin, S; Xie, M, 2018) |
| "Using our rat cholangiocarcinoma model, we demonstrated that thalidomide inhibited tumor growth and was associated with a decrease in expression of reduced eIF4E and VEGF expression; in addition, thalidomide preserved fast-twitch skeletal muscle fibers and was associated with decreased expression of TNFalpha and TGFbeta1." | 3.74 | Thalidomide attenuates tumor growth and preserves fast-twitch skeletal muscle fibers in cholangiocarcinoma rats. ( Liao, LM; Liu, KH; Ro, LS; Wu, YL; Yeh, TS, 2008) |
| "Thalidomide is being tested as an anti-HIV drug, a weight loss treatment, an immune system regulator, a tuberculosis treatment supplement, and a treatment for microsporidiosis." | 3.69 | Treatment for weight loss, tuberculosis and AIDS? ( , 1995) |
| "The management of cancer-related anorexia/cachexia syndrome (CACS) is a great challenge in clinical practice." | 2.77 | Clinical studies on the treatment of cancer cachexia with megestrol acetate plus thalidomide. ( Cao, YZ; Li, X; Peng, LM; Shi, YM; Wen, HS; Yang, F; Zhang, CC, 2012) |
| "Oesophageal cancer cachexia is a significant clinical problem, resulting in excessive morbidity and mortality." | 2.76 | Poor tolerability of thalidomide in end-stage oesophageal cancer. ( Cole, AT; Freeman, JG; Khan, ZH; Rennie, MJ; Selby, AL; Wilkes, EA, 2011) |
| "Thalidomide treatment appeared to reverse the loss of weight and lean body mass over the 2-week trial period." | 2.71 | Oesophageal cancer and cachexia: the effect of short-term treatment with thalidomide on weight loss and lean body mass. ( Austin, A; Cole, AT; Freeman, JG; Holt, M; Khan, ZH; MacDonald, I; Pye, D; Simpson, EJ, 2003) |
| " The Food and Drug Administration (FDA), Celgene, and AIDS activists eliminated the randomized dose portion of the program to allow physicians to determine the dosage to use." | 2.68 | Thalidomide's elusive access. ( Gilden, D, 1995) |
| "Studies have recruited heterogeneous cancer patient populations in late disease stages, and many had issues with accrual and attrition." | 2.61 | Anti-cytokines in the treatment of cancer cachexia. ( Prado, BL; Qian, Y, 2019) |
| "In patients with advanced cancer, AIDS and end-stage organ diseases, symptoms of cachexia syndrome include decrease in appetite, weight loss, decreased performance status, and an increase in the systemic inflammatory response." | 2.50 | Immunomodulatory agents for the treatment of cachexia. ( Bhargava, R; Chasen, M; Hirschman, S, 2014) |
| "Much of the success in the treatment of cachexia has come from agents capable of blocking protein degradation through the ubiquitin-proteasome proteolytic pathway." | 2.43 | Clinical anticachexia treatments. ( Tisdale, MJ, 2006) |
| "Thalidomide was first produced in Germany in the 1950s." | 2.42 | [Thalidomide--new prospective therapy in oncology]. ( Pałgan, I; Pałgan, K, 2003) |
| "Thalidomide was first used in the late 1950s but it was withdrawn from the market in the 1960s for its notorious teratogenic effects." | 2.42 | The promise of thalidomide: evolving indications. ( Joglekar, S; Levin, M, 2004) |
| "The activity of thalidomide in solid tumors is less prominent." | 2.42 | Thalidomide in cancer medicine. ( Bamias, A; Dimopoulos, MA; Eleutherakis-Papaiakovou, V, 2004) |
| "Thalidomide trials have been slow to recruit, therefore buyers clubs are working to make the drug available through their services." | 1.29 | Thalidomide and HIV: several possible uses. ( Smith, D, 1995) |
| "Thalidomide may cause birth defects, and larger doses can cause neuropathy or other adverse effects." | 1.29 | Wasting syndrome--affordable treatments. ( James, JS, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 17 (38.64) | 18.2507 |
| 2000's | 17 (38.64) | 29.6817 |
| 2010's | 10 (22.73) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Xie, M | 1 |
| Chen, X | 1 |
| Qin, S | 1 |
| Bao, Y | 1 |
| Bu, K | 1 |
| Lu, Y | 1 |
| Prado, BL | 1 |
| Qian, Y | 1 |
| Wen, HS | 1 |
| Li, X | 1 |
| Cao, YZ | 1 |
| Zhang, CC | 1 |
| Yang, F | 1 |
| Shi, YM | 1 |
| Peng, LM | 1 |
| Ritchie, CS | 1 |
| Currow, DC | 1 |
| Abernethy, AP | 1 |
| Kutner, JS | 1 |
| Chasen, M | 1 |
| Bhargava, R | 1 |
| Hirschman, S | 1 |
| Tassinari, D | 1 |
| Santelmo, C | 1 |
| Tombesi, P | 1 |
| Sartori, S | 1 |
| Mantovani, G | 2 |
| Macciò, A | 1 |
| Madeddu, C | 1 |
| Serpe, R | 1 |
| Massa, E | 1 |
| Dessì, M | 1 |
| Panzone, F | 1 |
| Contu, P | 1 |
| Wilkes, EA | 2 |
| Selby, AL | 1 |
| Cole, AT | 2 |
| Freeman, JG | 3 |
| Rennie, MJ | 1 |
| Khan, ZH | 2 |
| Reid, J | 1 |
| Mills, M | 1 |
| Cantwell, M | 1 |
| Cardwell, CR | 1 |
| Murray, LJ | 1 |
| Donnelly, M | 1 |
| Yennurajalingam, S | 1 |
| Willey, JS | 1 |
| Palmer, JL | 1 |
| Allo, J | 1 |
| Del Fabbro, E | 1 |
| Cohen, EN | 1 |
| Tin, S | 1 |
| Reuben, JM | 1 |
| Bruera, E | 5 |
| Simpson, EJ | 1 |
| Holt, M | 1 |
| MacDonald, I | 1 |
| Pye, D | 1 |
| Austin, A | 1 |
| Okafor, MC | 1 |
| Gordon, JN | 2 |
| Goggin, PM | 2 |
| Fanelli, M | 1 |
| Sarmiento, R | 1 |
| Gattuso, D | 1 |
| Carillio, G | 1 |
| Capaccetti, B | 1 |
| Vacca, A | 1 |
| Roccaro, AM | 1 |
| Gasparini, G | 1 |
| Pałgan, K | 1 |
| Pałgan, I | 1 |
| Joglekar, S | 1 |
| Levin, M | 1 |
| Eleutherakis-Papaiakovou, V | 1 |
| Bamias, A | 1 |
| Dimopoulos, MA | 1 |
| Stroud, M | 1 |
| Trebble, TM | 1 |
| Ellis, RD | 1 |
| Duncan, HD | 1 |
| Johns, T | 1 |
| Argilés, JM | 1 |
| Busquets, S | 1 |
| López-Soriano, FJ | 1 |
| Tisdale, MJ | 1 |
| Powell, RJ | 1 |
| Liu, KH | 1 |
| Liao, LM | 1 |
| Ro, LS | 1 |
| Wu, YL | 1 |
| Yeh, TS | 1 |
| Weinroth, SE | 1 |
| Parenti, DM | 1 |
| Simon, GL | 1 |
| Haslett, PA | 1 |
| Larkin, M | 1 |
| Neumann, CM | 1 |
| Pituskin, E | 1 |
| Calder, K | 2 |
| Ball, G | 1 |
| Hanson, J | 1 |
| Peuckmann, V | 1 |
| Fisch, M | 1 |
| Smith, D | 1 |
| Getty, J | 1 |
| Grunfeld, C | 1 |
| James, JS | 3 |
| Gilden, D | 1 |
| Baker, R | 1 |
| Cooper, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized, Double-blind Clinical Trial of the Use of Mirtazapine Versus Megestrol for the Control of Anorexia-cachexia in Cancer Patients in Palliative Care.[NCT03283488] | Phase 2 | 52 participants (Actual) | Interventional | 2019-03-26 | Completed | ||
| A Single-arm, Open, Prospective, Multi-center Study on Thalidomide Combined With First-line Chemotherapy and Monotherapy for Maintenance Treatment of Liver Metastases From Her2-negative Advanced Gastric Cancer[NCT05198856] | Phase 1/Phase 2 | 106 participants (Anticipated) | Interventional | 2022-03-10 | Not yet recruiting | ||
| Nabilone Effect on the Attenuation of Anorexia, Nutritional Status and Quality of Life in Patients With Anorexia Associated With Advanced Lung Cancer: Randomized Double Blind Clinical Trial[NCT02802540] | Phase 2/Phase 3 | 78 participants (Anticipated) | Interventional | 2014-12-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
16 reviews available for thalidomide and Cachexia
| Article | Year |
|---|---|
Anti-cytokines in the treatment of cancer cachexia.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cachexia; Cytokines; Etanercept; Forecast | 2019 |
Immunomodulatory agents for the treatment of cachexia.
Topics: Adipose Tissue; Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Appetite; C-Reacti | 2014 |
Thalidomide for managing cancer cachexia.
Topics: Adult; Anti-Inflammatory Agents; Cachexia; Humans; Immunosuppressive Agents; Neoplasms; Randomized C | 2012 |
Thalidomide for erythema nodosum leprosum and other applications.
Topics: Animals; Cachexia; Erythema Nodosum; Graft vs Host Disease; Humans; Leprosy, Lepromatous; Multiple M | 2003 |
Thalidomide and its derivatives: emerging from the wilderness.
Topics: Adjuvants, Immunologic; Cachexia; Crohn Disease; Graft vs Host Disease; Hematologic Neoplasms; Human | 2003 |
Thalidomide: a new anticancer drug?
Topics: Animals; Antineoplastic Agents; Cachexia; Hematologic Neoplasms; Humans; Neoplasms; Thalidomide | 2003 |
[Thalidomide--new prospective therapy in oncology].
Topics: Analgesics; Angiogenesis Inhibitors; Antineoplastic Agents; Cachexia; Clinical Trials as Topic; Huma | 2003 |
The promise of thalidomide: evolving indications.
Topics: Cachexia; Carcinoma, Renal Cell; Clinical Trials as Topic; Erythema Nodosum; Graft vs Host Disease; | 2004 |
Thalidomide in cancer medicine.
Topics: Angiogenesis Inhibitors; Cachexia; Clinical Trials as Topic; Graft vs Host Disease; Humans; Multiple | 2004 |
Thalidomide and cancer cachexia: old problem, new hope?
Topics: Angiogenesis Inhibitors; Cachexia; Humans; Neoplasms; Pancreatic Neoplasms; Thalidomide | 2005 |
The pivotal role of cytokines in muscle wasting during cancer.
Topics: Animals; Anorexia; Antibodies; Cachexia; Cytokines; Humans; Models, Biological; Muscle, Skeletal; Mu | 2005 |
Clinical anticachexia treatments.
Topics: Adipose Tissue; Adrenal Cortex Hormones; Cachexia; Eicosapentaenoic Acid; Energy Metabolism; Humans; | 2006 |
Wasting syndrome in AIDS: pathophysiologic mechanisms and therapeutic approaches.
Topics: Acetylcysteine; Acquired Immunodeficiency Syndrome; AIDS-Related Opportunistic Infections; Body Comp | 1995 |
Pharmacological treatment of cachexia: any progress?
Topics: Adrenal Cortex Hormones; Adrenergic beta-Agonists; Antiemetics; Antioxidants; Appetite Stimulants; C | 1998 |
Anticytokine approaches to the treatment of anorexia and cachexia.
Topics: Anorexia; Cachexia; Humans; Immunosuppressive Agents; Interleukin-1; Interleukin-6; Pentoxifylline; | 1998 |
Potential novel uses of thalidomide: focus on palliative care.
Topics: Angiogenesis Inhibitors; Animals; Cachexia; Cytokines; Erythema Nodosum; Graft vs Host Disease; Huma | 2000 |
13 trials available for thalidomide and Cachexia
| Article | Year |
|---|---|
Clinical studies on the treatment of cancer cachexia with megestrol acetate plus thalidomide.
Topics: Aged; Appetite Stimulants; Body Weight; Cachexia; Drug Therapy, Combination; Fatigue; Female; Hand S | 2012 |
Thalidomide in the treatment of cancer cachexia.
Topics: Aged; Angiogenesis Inhibitors; Anorexia; Cachexia; Drug Monitoring; Female; Gastrointestinal Neoplas | 2008 |
Randomized phase III clinical trial of five different arms of treatment in 332 patients with cancer cachexia.
Topics: Appetite Stimulants; Cachexia; Carnitine; Eicosapentaenoic Acid; Female; Humans; Interleukin-6; Male | 2010 |
Randomised phase III clinical trial of 5 different arms of treatment on 332 patients with cancer cachexia.
Topics: Aged; Body Composition; Cachexia; Carnitine; Contraceptives, Oral, Hormonal; Eicosapentaenoic Acid; | 2010 |
Poor tolerability of thalidomide in end-stage oesophageal cancer.
Topics: Aged; Aged, 80 and over; Cachexia; Double-Blind Method; Esophageal Neoplasms; Female; Humans; Male; | 2011 |
The role of thalidomide and placebo for the treatment of cancer-related anorexia-cachexia symptoms: results of a double-blind placebo-controlled randomized study.
Topics: Adult; Aged; Aged, 80 and over; Anorexia; Cachexia; Double-Blind Method; Female; Humans; Immunosuppr | 2012 |
Oesophageal cancer and cachexia: the effect of short-term treatment with thalidomide on weight loss and lean body mass.
Topics: Aged; Aged, 80 and over; Basal Metabolism; Body Composition; Body Mass Index; Cachexia; Energy Intak | 2003 |
Thalidomide in the treatment of cancer cachexia: a randomised placebo controlled trial.
Topics: Aged; Angiogenesis Inhibitors; Body Weight; Cachexia; Double-Blind Method; Female; Humans; Male; Nut | 2005 |
Thalidomide in patients with cachexia due to terminal cancer: preliminary report.
Topics: Aged; Appetite; Cachexia; Female; Humans; Hypnotics and Sedatives; Male; Neoplasm Metastasis; Neopla | 1999 |
Thalidomide: new expanded access for wasting.
Topics: Acquired Immunodeficiency Syndrome; Cachexia; Costs and Cost Analysis; Female; Hotlines; Humans; Imm | 1995 |
Thalidomide's elusive access.
Topics: Acquired Immunodeficiency Syndrome; Cachexia; Clinical Trials as Topic; Humans; Randomized Controlle | 1995 |
Thalidomide for mouth ulcers and wasting.
Topics: Cachexia; Double-Blind Method; HIV Infections; Humans; Placebos; Stomatitis, Aphthous; Thalidomide | 1995 |
Thalidomide used to treat chronic diarrhea in HIV-positive patients.
Topics: Cachexia; Diarrhea; Double-Blind Method; HIV Infections; Humans; Thalidomide; Treatment Outcome | 1996 |
15 other studies available for thalidomide and Cachexia
| Article | Year |
|---|---|
Clinical study on thalidomide combined with cinobufagin to treat lung cancer cachexia.
Topics: Aged; Bufanolides; Cachexia; Drug Therapy, Combination; Female; Humans; Kaplan-Meier Estimate; Lung | 2018 |
Multisite studies offer a solution to recruitment challenges in palliative care studies.
Topics: Anorexia; Cachexia; Female; Humans; Immunosuppressive Agents; Male; Neoplasms; Thalidomide | 2013 |
Thalidomide: an effective anabolic agent in gastrointestinal cancer cachexia.
Topics: Anabolic Agents; Cachexia; Gastrointestinal Neoplasms; Humans; Thalidomide | 2006 |
Thalidomide. Treat with caution!
Topics: Adult; Aged, 80 and over; Angiodysplasia; Angiogenesis Inhibitors; Cachexia; Drug Design; Female; Hu | 2006 |
Thalidomide attenuates tumor growth and preserves fast-twitch skeletal muscle fibers in cholangiocarcinoma rats.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cachexia | 2008 |
Thwarting the dwindling progression of cachexia.
Topics: Cachexia; HIV Infections; Humans; Neoplasms; Thalidomide | 1998 |
Thalidomide for night sweats in patients with advanced cancer.
Topics: Adenocarcinoma; Cachexia; Colonic Neoplasms; Female; Humans; Hypnotics and Sedatives; Middle Aged; S | 2000 |
Thalidomide, the FDA, and us -- what do you have? Underground compassionate use. Food and Drug Administration.
Topics: Acquired Immunodeficiency Syndrome; Cachexia; Clinical Trials as Topic; Humans; Teratogens; Thalidom | 1995 |
Thalidomide and HIV: several possible uses.
Topics: AIDS-Related Opportunistic Infections; Cachexia; Clinical Trials as Topic; HIV Infections; Humans; N | 1995 |
Turning the corner on wasting? A symposium on wasting disorders.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cachexia; Endocrine System Diseases; Humans; M | 1995 |
State of the art in wasting: an interview with Carl Grunfeld, PhD. Interview by Jeff Getty.
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Opportunistic Infections; Animals; Cachexia; Endocr | 1995 |
Wasting syndrome--affordable treatments.
Topics: Acquired Immunodeficiency Syndrome; Cachexia; Costs and Cost Analysis; Dronabinol; Exercise Therapy; | 1995 |
Treatment for weight loss, tuberculosis and AIDS?
Topics: Acquired Immunodeficiency Syndrome; Cachexia; Clinical Trials as Topic; Humans; Stomatitis, Aphthous | 1995 |
Thalidomide for wasting syndrome: progress toward compromise.
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Opportunistic Infections; Cachexia; Dose-Response R | 1995 |
Thalidomide, gentrified.
Topics: Acquired Immunodeficiency Syndrome; Cachexia; Drug Costs; Female; Humans; Male; Stomatitis, Aphthous | 1996 |